Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 12/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 0.74 |
| ▸ | DRD1 | P21728 | 2/20 | 0.74 |
| ▸ | DRD4 | P21917 | 2/20 | 0.74 |
| ▸ | DRD5 | P21918 | 2/20 | 0.74 |
| ▸ | HTR2A | P28223 | 2/20 | 0.74 |
| ▸ | HTR2C | P28335 | 2/20 | 0.74 |
| ▸ | DRD3 | P35462 | 2/20 | 0.74 |
| ▸ | ABCB1 | P08183 | 6/20 | 0.46 |
| ▸ | ABCC1 | P33527 | 3/20 | 0.44 |
| ▸ | HTR5A | P47898 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29042970 | 1.00 | DRD2 (1.00) | DRD2HTR1ADRD1DRD4DRD5 | |
| SCHEMBL29043054 | 0.86 | DRD2 (1.00) | DRD2HTR1ADRD1DRD4DRD5 | |
| SCHEMBL31478045 | 0.86 | DRD2 (1.00) | DRD2HTR1ADRD1DRD4DRD5 | |
| SCHEMBL29042952 | 0.85 | DRD2 (1.00) | DRD2HTR1ADRD1DRD4DRD5 | |
| SCHEMBL31478063 | 0.85 | DRD2 (1.00) | DRD2HTR1ADRD1DRD4DRD5 | |
| SCHEMBL30524212 | 0.84 | DRD2 (0.80) | DRD2HTR1ADRD1DRD4DRD5 | |
| SCHEMBL25330929 | 0.83 | DRD2 (1.00) | DRD2HTR1ADRD1DRD4DRD5 | |
| SCHEMBL31478050 | 0.83 | DRD2 (1.00) | DRD2HTR1ADRD1DRD4DRD5 | |
| SCHEMBL31478006 | 0.81 | DRD2 (1.00) | DRD2HTR1ADRD1DRD4DRD5 | |
| SCHEMBL31478004 | 0.81 | DRD2 (1.00) | DRD2HTR1ADRD1DRD4DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250109139-A1 | TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | CENTER FOR EXCELLENCE IN MOLECULAR CELL SCIENCE, CHINESE ACADEMY OF SCIENCES (CN) | 2025-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250109139-A1 | TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | PARK7, HADH, BDNF | DRD2 458/4885HTR1A 109/4885DRD1 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.